Global Recurrent Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2021-2027

Global Recurrent Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 AU-105
1.2.3 Axitinib
1.2.4 AXL-1717
1.2.5 AZD-7451
1.2.6 Others
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Perspective (2016-2027)
2.2 Recurrent Glioblastoma Multiforme Treatment Growth Trends by Regions
2.2.1 Recurrent Glioblastoma Multiforme Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Recurrent Glioblastoma Multiforme Treatment Industry Dynamic
2.3.1 Recurrent Glioblastoma Multiforme Treatment Market Trends
2.3.2 Recurrent Glioblastoma Multiforme Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2016-2021)
3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2020
3.5 Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Area Served
3.6 Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
3.7 Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2016-2021)
4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2022-2027)
5 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Application (2016-2021)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
6.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type
6.2.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
6.2.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
6.2.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application
6.3.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
6.3.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
6.3.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country
6.4.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
6.4.2 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
7.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type
7.2.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
7.2.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
7.2.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application
7.3.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
7.3.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
7.3.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country
7.4.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
7.4.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type
8.2.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application
8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region
8.4.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
9.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type
9.2.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
9.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application
9.3.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
9.4 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country
9.4.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size (2016-2027)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type
10.2.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application
10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country
10.4.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Details
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 Boston Biomedical, Inc.
11.2.1 Boston Biomedical, Inc. Company Details
11.2.2 Boston Biomedical, Inc. Business Overview
11.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.2.5 Boston Biomedical, Inc. Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Details
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Cantex Pharmaceuticals, Inc.
11.4.1 Cantex Pharmaceuticals, Inc. Company Details
11.4.2 Cantex Pharmaceuticals, Inc. Business Overview
11.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.4.5 Cantex Pharmaceuticals, Inc. Recent Development
11.5 Cavion LLC
11.5.1 Cavion LLC Company Details
11.5.2 Cavion LLC Business Overview
11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction
11.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.5.5 Cavion LLC Recent Development
11.6 Celldex Therapeutics, Inc.
11.6.1 Celldex Therapeutics, Inc. Company Details
11.6.2 Celldex Therapeutics, Inc. Business Overview
11.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.6.5 Celldex Therapeutics, Inc. Recent Development
11.7 Coherus BioSciences, Inc.
11.7.1 Coherus BioSciences, Inc. Company Details
11.7.2 Coherus BioSciences, Inc. Business Overview
11.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.7.5 Coherus BioSciences, Inc. Recent Development
11.8 Cortice Biosciences, Inc.
11.8.1 Cortice Biosciences, Inc. Company Details
11.8.2 Cortice Biosciences, Inc. Business Overview
11.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.8.5 Cortice Biosciences, Inc. Recent Development
11.9 Eisai
11.9.1 Eisai Company Details
11.9.2 Eisai Business Overview
11.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction
11.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.9.5 Eisai Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Details
11.10.2 Eli Lilly and Company Business Overview
11.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.10.5 Eli Lilly and Company Recent Development
11.11 EnGeneIC Ltd
11.11.1 EnGeneIC Ltd Company Details
11.11.2 EnGeneIC Ltd Business Overview
11.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
11.11.4 EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.11.5 EnGeneIC Ltd Recent Development
11.12 ERC Belgium SA
11.12.1 ERC Belgium SA Company Details
11.12.2 ERC Belgium SA Business Overview
11.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
11.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.12.5 ERC Belgium SA Recent Development
11.13 GenSpera, Inc.
11.13.1 GenSpera, Inc. Company Details
11.13.2 GenSpera, Inc. Business Overview
11.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.13.5 GenSpera, Inc. Recent Development
11.14 Genzyme Corporation
11.14.1 Genzyme Corporation Company Details
11.14.2 Genzyme Corporation Business Overview
11.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
11.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.14.5 Genzyme Corporation Recent Development
11.15 GW Pharmaceuticals Plc
11.15.1 GW Pharmaceuticals Plc Company Details
11.15.2 GW Pharmaceuticals Plc Business Overview
11.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Introduction
11.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.15.5 GW Pharmaceuticals Plc Recent Development
11.16 ImmunoCellular Therapeutics, Ltd.
11.16.1 ImmunoCellular Therapeutics, Ltd. Company Details
11.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview
11.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Introduction
11.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021)
11.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of AU-105
Table 3. Key Players of Axitinib
Table 4. Key Players of AXL-1717
Table 5. Key Players of AZD-7451
Table 6. Key Players of Others
Table 7. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2016-2021)
Table 11. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2022-2027)
Table 13. Recurrent Glioblastoma Multiforme Treatment Market Trends
Table 14. Recurrent Glioblastoma Multiforme Treatment Market Drivers
Table 15. Recurrent Glioblastoma Multiforme Treatment Market Challenges
Table 16. Recurrent Glioblastoma Multiforme Treatment Market Restraints
Table 17. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players (2016-2021)
Table 19. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2020)
Table 20. Ranking of Global Top Recurrent Glioblastoma Multiforme Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
Table 24. Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Boehringer Ingelheim GmbH Company Details
Table 65. Boehringer Ingelheim GmbH Business Overview
Table 66. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product
Table 67. Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 68. Boehringer Ingelheim GmbH Recent Development
Table 69. Boston Biomedical, Inc. Company Details
Table 70. Boston Biomedical, Inc. Business Overview
Table 71. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 72. Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 73. Boston Biomedical, Inc. Recent Development
Table 74. Bristol-Myers Squibb Company Company Details
Table 75. Bristol-Myers Squibb Company Business Overview
Table 76. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product
Table 77. Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 78. Bristol-Myers Squibb Company Recent Development
Table 79. Cantex Pharmaceuticals, Inc. Company Details
Table 80. Cantex Pharmaceuticals, Inc. Business Overview
Table 81. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 82. Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 83. Cantex Pharmaceuticals, Inc. Recent Development
Table 84. Cavion LLC Company Details
Table 85. Cavion LLC Business Overview
Table 86. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product
Table 87. Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 88. Cavion LLC Recent Development
Table 89. Celldex Therapeutics, Inc. Company Details
Table 90. Celldex Therapeutics, Inc. Business Overview
Table 91. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 92. Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 93. Celldex Therapeutics, Inc. Recent Development
Table 94. Coherus BioSciences, Inc. Company Details
Table 95. Coherus BioSciences, Inc. Business Overview
Table 96. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 97. Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 98. Coherus BioSciences, Inc. Recent Development
Table 99. Cortice Biosciences, Inc. Company Details
Table 100. Cortice Biosciences, Inc. Business Overview
Table 101. Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 102. Cortice Biosciences, Inc. Recent Development
Table 103. Eisai Company Details
Table 104. Eisai Business Overview
Table 105. Eisai Recurrent Glioblastoma Multiforme Treatment Product
Table 106. Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 107. Eisai Recent Development
Table 108. Eli Lilly and Company Company Details
Table 109. Eli Lilly and Company Business Overview
Table 110. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product
Table 111. Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 112. Eli Lilly and Company Recent Development
Table 113. EnGeneIC Ltd Company Details
Table 114. EnGeneIC Ltd Business Overview
Table 115. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product
Table 116. EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 117. EnGeneIC Ltd Recent Development
Table 118. ERC Belgium SA Company Details
Table 119. ERC Belgium SA Business Overview
Table 120. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product
Table 121. ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 122. ERC Belgium SA Recent Development
Table 123. GenSpera, Inc. Company Details
Table 124. GenSpera, Inc. Business Overview
Table 125. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product
Table 126. GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 127. GenSpera, Inc. Recent Development
Table 128. Genzyme Corporation Company Details
Table 129. Genzyme Corporation Business Overview
Table 130. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product
Table 131. Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 132. Genzyme Corporation Recent Development
Table 133. GW Pharmaceuticals Plc Company Details
Table 134. GW Pharmaceuticals Plc Business Overview
Table 135. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product
Table 136. GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 137. GW Pharmaceuticals Plc Recent Development
Table 138. ImmunoCellular Therapeutics, Ltd. Company Details
Table 139. ImmunoCellular Therapeutics, Ltd. Business Overview
Table 140. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product
Table 141. ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2016-2021) & (US$ Million)
Table 142. ImmunoCellular Therapeutics, Ltd. Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type: 2020 VS 2027
Figure 2. AU-105 Features
Figure 3. Axitinib Features
Figure 4. AXL-1717 Features
Figure 5. AZD-7451 Features
Figure 6. Others Features
Figure 7. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Recurrent Glioblastoma Multiforme Treatment Report Years Considered
Figure 12. Global Recurrent Glioblastoma Multiforme Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2022-2027)
Figure 16. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players in 2020
Figure 17. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue in 2020
Figure 19. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 23. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 24. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 25. United States Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2016-2027)
Figure 29. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2016-2027)
Figure 30. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2016-2027)
Figure 31. Germany Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Fig

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs